| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell | 8 | 2024 | 149 | 3.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 20 | 2024 | 1187 | 2.760 |
Why?
|
| Immunotherapy, Adoptive | 14 | 2024 | 894 | 1.930 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2024 | 609 | 1.510 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2024 | 177 | 1.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2024 | 169 | 1.470 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2023 | 31 | 1.380 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 63 | 1.330 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2024 | 151 | 1.160 |
Why?
|
| Antigens, CD19 | 5 | 2024 | 181 | 1.110 |
Why?
|
| Graft vs Host Disease | 10 | 2024 | 619 | 0.980 |
Why?
|
| Hematologic Neoplasms | 5 | 2024 | 294 | 0.940 |
Why?
|
| Lymphoma, Follicular | 3 | 2020 | 30 | 0.900 |
Why?
|
| Hodgkin Disease | 3 | 2020 | 298 | 0.780 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1356 | 0.750 |
Why?
|
| Primary Myelofibrosis | 2 | 2020 | 50 | 0.740 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 25 | 0.690 |
Why?
|
| Antigens, CD20 | 1 | 2020 | 40 | 0.690 |
Why?
|
| Transplantation Conditioning | 8 | 2020 | 300 | 0.650 |
Why?
|
| Aged | 32 | 2024 | 21773 | 0.630 |
Why?
|
| Transplantation, Autologous | 6 | 2021 | 286 | 0.600 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 127 | 0.600 |
Why?
|
| SEER Program | 1 | 2019 | 224 | 0.580 |
Why?
|
| Rituximab | 5 | 2024 | 166 | 0.580 |
Why?
|
| Middle Aged | 34 | 2024 | 29397 | 0.580 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 42 | 0.570 |
Why?
|
| Transplantation, Homologous | 5 | 2019 | 690 | 0.560 |
Why?
|
| Pyrazoles | 6 | 2024 | 331 | 0.560 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 44 | 0.550 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 128 | 0.540 |
Why?
|
| Standard of Care | 1 | 2018 | 136 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 1317 | 0.510 |
Why?
|
| Lymphoma | 4 | 2023 | 336 | 0.500 |
Why?
|
| Sulfonamides | 4 | 2024 | 287 | 0.500 |
Why?
|
| Humans | 59 | 2025 | 134152 | 0.490 |
Why?
|
| Pyrimidines | 7 | 2024 | 418 | 0.480 |
Why?
|
| Recurrence | 6 | 2024 | 1472 | 0.470 |
Why?
|
| Doxorubicin | 3 | 2024 | 303 | 0.450 |
Why?
|
| Medicare | 1 | 2018 | 466 | 0.440 |
Why?
|
| Adult | 29 | 2024 | 31943 | 0.440 |
Why?
|
| Aged, 80 and over | 12 | 2024 | 7216 | 0.410 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 1853 | 0.400 |
Why?
|
| Cyclophosphamide | 6 | 2024 | 426 | 0.390 |
Why?
|
| Retrospective Studies | 23 | 2024 | 17540 | 0.390 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 567 | 0.390 |
Why?
|
| Male | 33 | 2024 | 66125 | 0.350 |
Why?
|
| Survival Analysis | 6 | 2021 | 1599 | 0.350 |
Why?
|
| Treatment Outcome | 16 | 2024 | 13074 | 0.340 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1391 | 0.340 |
Why?
|
| Female | 33 | 2024 | 71926 | 0.340 |
Why?
|
| Etoposide | 3 | 2024 | 120 | 0.330 |
Why?
|
| Allografts | 2 | 2023 | 198 | 0.330 |
Why?
|
| Neoplasms | 2 | 2024 | 3038 | 0.320 |
Why?
|
| Prednisone | 3 | 2024 | 289 | 0.320 |
Why?
|
| Vincristine | 3 | 2024 | 196 | 0.320 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 1812 | 0.310 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2019 | 12 | 0.300 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 128 | 0.290 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 307 | 0.280 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 503 | 0.280 |
Why?
|
| Survival Rate | 4 | 2019 | 2218 | 0.260 |
Why?
|
| Boron Compounds | 2 | 2024 | 34 | 0.260 |
Why?
|
| Adenine | 3 | 2024 | 122 | 0.250 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 287 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 825 | 0.250 |
Why?
|
| Glycine | 2 | 2024 | 173 | 0.240 |
Why?
|
| Young Adult | 8 | 2021 | 9944 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 166 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 2 | 2019 | 362 | 0.220 |
Why?
|
| Genetics, Population | 1 | 2025 | 198 | 0.210 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 51 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 703 | 0.200 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2019 | 11 | 0.190 |
Why?
|
| Autografts | 2 | 2019 | 29 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 157 | 0.190 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 972 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 342 | 0.180 |
Why?
|
| Piperidines | 2 | 2020 | 240 | 0.180 |
Why?
|
| Budesonide | 1 | 2021 | 21 | 0.180 |
Why?
|
| Prognosis | 3 | 2019 | 5086 | 0.180 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 15 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 216 | 0.170 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 109 | 0.170 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2020 | 15 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 79 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 125 | 0.170 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 74 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 104 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 97 | 0.160 |
Why?
|
| Febrile Neutropenia | 1 | 2019 | 15 | 0.160 |
Why?
|
| Steroids | 1 | 2020 | 213 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 202 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 316 | 0.150 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 63 | 0.150 |
Why?
|
| Melphalan | 1 | 2018 | 45 | 0.150 |
Why?
|
| Transplantation, Haploidentical | 1 | 2018 | 16 | 0.140 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 35 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 63 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 137 | 0.140 |
Why?
|
| Etanercept | 1 | 2017 | 47 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 385 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2019 | 202 | 0.130 |
Why?
|
| Disease Management | 2 | 2018 | 567 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 1072 | 0.130 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 53 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2022 | 752 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2017 | 367 | 0.130 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 64 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 437 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2018 | 1258 | 0.120 |
Why?
|
| Remission Induction | 3 | 2023 | 310 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5477 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2019 | 429 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 2997 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 704 | 0.110 |
Why?
|
| United States | 5 | 2024 | 11763 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1200 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1310 | 0.110 |
Why?
|
| Pneumonia | 1 | 2017 | 343 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 807 | 0.100 |
Why?
|
| Plasmacytoma | 1 | 2013 | 9 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 772 | 0.100 |
Why?
|
| Cytokines | 1 | 2018 | 1401 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 225 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 2 | 2024 | 31 | 0.090 |
Why?
|
| Insurance, Health | 2 | 2024 | 145 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2013 | 186 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 293 | 0.080 |
Why?
|
| Outpatients | 2 | 2024 | 276 | 0.080 |
Why?
|
| Adolescent | 4 | 2023 | 20624 | 0.080 |
Why?
|
| Nitriles | 2 | 2020 | 155 | 0.080 |
Why?
|
| Busulfan | 2 | 2020 | 45 | 0.080 |
Why?
|
| Methotrexate | 2 | 2024 | 354 | 0.080 |
Why?
|
| Vidarabine | 2 | 2020 | 78 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2020 | 108 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2578 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 556 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2019 | 3178 | 0.070 |
Why?
|
| Obesity | 1 | 2018 | 2446 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 3416 | 0.060 |
Why?
|
| Latin America | 1 | 2025 | 99 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 67 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 83 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2025 | 333 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2024 | 69 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 294 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 175 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 134 | 0.050 |
Why?
|
| Haplotypes | 1 | 2025 | 560 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2024 | 125 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 76 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 169 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2023 | 294 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2024 | 724 | 0.050 |
Why?
|
| Neutropenia | 1 | 2023 | 205 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2025 | 789 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 285 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 563 | 0.040 |
Why?
|
| DNA Topoisomerase IV | 1 | 2020 | 13 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 322 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2020 | 27 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 429 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 732 | 0.040 |
Why?
|
| Software | 1 | 2025 | 735 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 514 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 382 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 320 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2020 | 264 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 6610 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 52 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 611 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 182 | 0.040 |
Why?
|
| Propylene Glycol | 1 | 2018 | 9 | 0.040 |
Why?
|
| Exanthema | 1 | 2019 | 71 | 0.040 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 2 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 964 | 0.040 |
Why?
|
| Genome, Human | 1 | 2025 | 1351 | 0.030 |
Why?
|
| Binding Sites | 1 | 2020 | 1384 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 834 | 0.030 |
Why?
|
| Fever | 1 | 2019 | 312 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2018 | 374 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2018 | 539 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1249 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 11181 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2947 | 0.030 |
Why?
|
| Graft Survival | 1 | 2018 | 557 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1740 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1167 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 547 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 433 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2266 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1146 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1157 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 2160 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1488 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2013 | 57 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 3798 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 1578 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5222 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 19055 | 0.020 |
Why?
|
| Animals | 1 | 2023 | 36557 | 0.010 |
Why?
|